MLKL and colorectal cancer: Yet, curiously, despite some groups reporting that MLKL-deficient mice are protected from DSS-induced colitis and colitis-associated tumourigenesis [214,215], other studies, including those using littermate control animals, found little-to-no role for RIPK1 kinase, RIPK3- or MLKL-dependent necroptotic signalling in DSS-induced colitis and/or colorectal cancer [162,216].